TGM2 belongs to the family of tissue transglutaminases and it is significantly increased in several types of cancers, including breast, ovarian, prostate, and pancreatic cancers, and thus positively correlated with poor prognosis 37, consistent with our analysis of the public clinical database analysis (Figure 1J). Here, TGM2 is linked to cancer.